According to a recent announcement from Soligenix Inc., the company has successfully applied its heat-stabilization technology to its human papillomavirus (HPV) vaccine.
The company -- a late-stage biopharmaceutical company that creates products for the unmet medical needs of patients with biodefense, oncology and inflammation issues -- recently published data from its University of Colorado study that demonstrates that the HPV vaccine is now heat stable. The scientists converted a virus-like, particle-based vaccine that needed cold-chain storage with a subunit, alum-adjuvanted vaccine that showed stable results at ambient temperatures, resulting in a vaccine that is heat stable.
"The use of subunit vaccines has always been hindered by concerns about thermostability,” co-Director of the Center for Pharmaceutical Biotechnology at the University of Colorado Theodore Randolph said. “The use of this technology, invented at the University of Colorado, clearly overcomes these concerns and offers broad applicability in many commercial indications."
Randloph said in addition to the cost-savings incurred for vaccines for the developed world, the use of this technology also offers the opportunity for more effective vaccination in the developing world.
"This is the first application of ThermoVax, our proprietary thermostabilization system, with a commercial vaccine indication,” Soligenix CEO and President Christopher Schaber said. “This work illustrates the broad applicability of this technology platform. We are continuing to develop ThermoVax in the context of our RiVax vaccine under a recent NIAID contract award of up to $24.7 million over six years."